The CH50 assay, also known as 50% hemolytic complement titer determination, is a functional test that quantifies the total activity of the classical complement pathway by measuring the serum dilution that lyses 50% of antibody-sensitized sheep erythrocytes. This article provides a comprehensive technical overview of the assay principle, sample requirements, procedural methodology, calculation, quality control, and its clinical and pharmaceutical applications.
Technical Overview
The CH50 assay (50% hemolytic complement titer determination, or total hemolytic complement assay) is the reference functional method for evaluating the integrated activity of the complete classical complement pathway, encompassing components C1 through C9. The assay is based on the ability of complement proteins in serum to lyse sheep red blood cells (SRBC) that have been sensitized with specific anti-erythrocyte antibodies (hemolysin or amboceptor), forming so-called EA cells (erythrocyte–antibody complexes).
When serial dilutions of test serum are incubated with a standardized EA cell suspension, antibody-mediated classical pathway activation generates membrane attack complexes on the erythrocyte surface, producing hemoglobin release that is quantified spectrophotometrically. The hemolytic response follows the sigmoidal von Krogh relationship: the degree of lysis is proportional to complement concentration only over a narrow range, and the point of 50% lysis lies on the steepest and most linear portion of the dose–response curve. Consequently, the serum dilution producing exactly 50% hemolysis provides the most sensitive and reproducible endpoint, and the result is reported as CH50 units per milliliter (U/mL) or as a percentage of a pooled normal reference serum.
Because lysis requires every classical pathway component to be present and functional, the CH50 assay serves as a global screening test: a marked reduction or absence of activity indicates either a genetically determined deficiency of any single component or acquired consumption of complement in immune complex disease. Laboratory reference intervals are typically in the range of 26–58 U/mL, although each laboratory must establish its own validated interval using local population data.
Testing Samples
Human Serum
Serum collected in plain tubes without anticoagulant is the specimen of choice. Blood should be allowed to clot for 30–60 minutes at room temperature and centrifuged promptly, since complement proteins are thermolabile and degrade rapidly at ambient temperature. Plasma is generally unacceptable because chelating anticoagulants such as EDTA and citrate bind the divalent calcium and magnesium ions essential for complement activation, and heparin may also interfere with the reaction.
Animal Serum and Biological Raw Materials
The assay is equally applicable to animal sera used in preclinical immunology studies and to source materials in biologics manufacturing, most notably guinea pig serum employed as an exogenous complement reagent in potency tests and complement-dependent cytotoxicity (CDC) assays. Batch-to-batch qualification of such complement raw materials relies on 50% hemolytic titer determination to confirm adequate functional potency.
Reference and Control Sera
A pooled normal human serum standard or an accredited reference material should be analyzed in parallel with every run to normalize results between assays. Samples must be free of gross hemolysis, severe lipemia, and microbial contamination, and should be stored at −70 °C or below in single-use aliquots to avoid repeated freeze–thaw cycles, which progressively destroy complement activity.
Testing Items
The core deliverable of the test is the total functional activity of the classical complement pathway, expressed as the CH50 titer in U/mL. Depending on the testing program, the following items may be included:
- CH50 titer (50% hemolytic complement activity) of serum or biological source material
- Alternative pathway activity (AH50) in parallel, to discriminate classical from alternative pathway defects
- Relative potency of complement raw materials against an accredited reference standard
- Interpretive assessment of hypocomplementemia, normocomplementemia, or elevated complement activity, typically supported by measurement of individual components such as C3 and C4
Testing Methods
Preparation of Sensitized Erythrocytes (EA Cells)
Sheep red blood cells are washed in buffered saline and standardized to a defined cell concentration. The cells are then sensitized by incubation with an optimized, subagglutinating dilution of rabbit anti-sheep erythrocyte hemolysin at 37 °C. The hemolysin working dilution must be titrated in advance so that erythrocytes are optimally sensitized without antibody excess, which would otherwise shift the hemolytic curve and distort the endpoint.
Reaction Setup and Incubation
Serial two-fold (or finer) dilutions of the test serum are prepared in gelatin veronal-buffered saline containing calcium and magnesium ions (GVB2+), which preserves the ionic requirements of the classical pathway. Equal volumes of each dilution are mixed with the standardized EA suspension and incubated in a 37 °C water bath for 30 to 60 minutes with gentle mixing. System controls include a 100% hemolysis control (erythrocytes lysed in distilled water), a 0% hemolysis control (cells in buffer without serum), and a reagent blank.
Spectrophotometric Quantification
After incubation, the reaction is arrested by chilling in an ice bath or by adding EDTA-containing stop solution, and the tubes are centrifuged to pellet intact cells. Hemoglobin released into the supernatant is measured by absorbance at 540–541 nm. The percentage of hemolysis for each dilution is calculated as: percent lysis = (A(sample) − A(blank)) / (A(100%) − A(blank)) × 100.
Calculation of the CH50 Titer
The von Krogh transformation is applied by plotting log[y/(1−y)], where y is the fractional hemolysis, against the logarithm of serum dilution. The resulting straight line is used to interpolate the dilution corresponding to exactly 50% lysis. The reciprocal of this dilution, corrected for the volume of serum in the reaction mixture, yields the CH50 value in units per milliliter, where one CH50 unit is defined as the quantity of complement required to lyse 50% of the standardized EA cell suspension under the assay conditions.
Quality Control and Method Variants
Each analytical run must satisfy predefined acceptance criteria for the 100% and 0% hemolysis controls, cell concentration standardization, incubation temperature, and replicate precision, with reference serum values falling within established control limits. Accredited third-party laboratories performing this test typically operate under medical laboratory quality frameworks such as ISO 15189, and methods used to evaluate complement activation of blood-contacting medical devices align with ISO 10993-4. In clinical settings, automated alternatives such as liposome-based turbidimetric or kinetic assays are available for high-throughput screening, while the manual 50% endpoint method remains the reference procedure.
Applications
The 50% hemolytic titer determination is applied across clinical diagnostics, pharmaceutical quality control, and biomedical research:
- Screening for hereditary deficiencies of classical pathway components (C1–C9), which predispose patients to recurrent infections and autoimmune syndromes
- Monitoring disease activity in systemic lupus erythematosus, cryoglobulinemia, and immune complex vasculitides, where active disease is frequently accompanied by falling CH50 values
- Evaluation of hypocomplementemic conditions including post-infectious and membranoproliferative glomerulonephritis and hereditary angioedema
- Monitoring of patients receiving terminal complement inhibition therapy, in which CH50 suppression confirms pharmacodynamic blockade
- Qualification of guinea pig complement and other animal serum raw materials used in vaccine potency testing and CDC-based bioassays
- Hemocompatibility assessment of medical devices and biomaterials in accordance with ISO 10993-4
- Preclinical immunotoxicology, vaccine immunogenicity studies, and adjuvant evaluation in animal models
FAQ
Why is the 50% lysis endpoint used rather than 100%? The complement–hemolysis dose–response curve is sigmoidal. Near 100% lysis, large changes in complement concentration produce negligible changes in absorbance, whereas the 50% point lies on the steepest portion of the curve, providing maximum analytical sensitivity and precision for titer determination.
What does a decreased CH50 result indicate? A low or absent CH50 indicates reduced functional activity of the classical pathway, caused either by inherited deficiency of a single component or by acquired activation and consumption in immune complex disease. Results are interpreted together with C3 and C4 concentrations and the clinical context.
What does an elevated CH50 mean? Increased values are frequently observed during the acute-phase response, in inflammatory disorders, and in some malignancies, reflecting elevated synthesis of complement proteins.
How should samples be handled to preserve complement activity? Serum must be separated promptly, kept cold, and frozen at −70 °C or below as soon as possible. Repeated freeze–thaw cycles, prolonged room-temperature storage, heat inactivation, and chelating anticoagulants must all be strictly avoided.
How does CH50 differ from AH50? CH50 evaluates the classical pathway using antibody-sensitized erythrocytes, while AH50 evaluates the alternative pathway using unsensitized rabbit erythrocytes in a magnesium-only buffer. Running both assays in parallel allows localization of a defect to a specific pathway or shared terminal component.
Is the assay suitable for pharmaceutical quality control? Yes. The 50% hemolytic titer method is a recognized pharmacopoeial-style potency procedure for qualifying complement-containing raw materials and for supporting CDC-based release assays, and accredited third-party laboratories routinely perform it under validated, GMP-compatible protocols.
